We are thrilled to announce that DeepSeq.AI (DeepSeq) has been selected as one of the few award winners (out of about 500 applicants) under the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) AIxBTO initiative! We are one of just 16 DARPA AI BTO Pitch Day awardees in our area of Biomanufacturing / Synthetic Biology, and we understand the only awardee in our area with the scope of advancing a generalized AI/assay-based protein drug discovery platform to help tackle future pandemic threats, aligning with DARPA BTO's mission to drive transformative science.
DeepSeq is proud to be part of DARPA's groundbreaking BTO initiative, leveraging AI to protect against future pandemic threats. While the immediate threat of COVID-19 may have subsided, there is still an ongoing threat of emerging pathogens and the possibility of future worldwide pandemics. The silver lining in the COVID-19 pandemic was that it proved that biotech innovation could help save countless lives—from the deployment of mRNA vaccines to prevent disease in the larger population, to the rapid development of antibody drugs that served as life-saving measures for infected individuals.
At DeepSeq, we are uniquely positioned to help the US and the world address future pandemic challenges. Our proprietary platform combines cost-effective, large-scale protein screening with AI-driven sequence-to-function modeling, enabling the rapid design of high-quality and safe biologics against pathogens. Our breakthrough approach can assist in unlocking more universal therapeutics, permitting a rapid-response framework against emerging pathogenic threats.
We are honored and excited to take on this vital scientific challenge, and we extend our deepest gratitude to DARPA's BTO for their trust and support. Together with DARPA, we are helping shape a more resilient future for global human health.
